Together, our data indicate that effective control of APECED-associated autoimmunity requires direct suppression of the IFN-γ-JAK2 axis rather than generalized lymphocyte inhibition and suggest that selective JAK2 targeting may represent a rational strategy to preserve therapeutic efficacy while minimizing disruption of JAK1-and γc-dependent immune functions. This evidence concerns the gene JAK1 and Autoimmunity.